Literature summary for 1.1.1.187 extracted from

Chiku, K.; Tsunemi, K.; Yamamoto, M.; Ohnishi-Kameyama, M.; Yoshida, M.; Ishii, T.; Taguchi, F.; Iwaki, M.; Ichinose, Y.; Ono, H.
Defects in D-rhamnosyl residue biosynthetic genes affect lipopolysaccharide structure, motility, and cell-surface hydrophobicity in Pseudomonas syringae pathovar glycinea race 4 (2013), Biosci. Biotechnol. Biochem., 77, 505-510.

Search for more literature for 1.1.1.187

Cloned(Commentary)

Cloned (Comment)	Organism
gene rmd	Pseudomonas syringae

Protein Variants

Protein Variants	Comment	Organism
additional information	construction of enzyme deletion mutant DELTArmd. The mutant strain shows highly reduced antimicrobial susceptibility with chloramphenicol, ampicillin or spectinomycin. Structural analysis of lipopolysaccharides in the mutant strain, NMR and mass spectrrometry analysis, overview	Pseudomonas syringae

Organism

Organism	UniProt	Comment	Textmining
Pseudomonas syringae	-	pathovar glycinea	-

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
GDP-4-dehydro-alpha-D-rhamnose + NAD(P)H + H+	-	Pseudomonas syringae	GDP-alpha-D-rhamnose + NAD(P)+	-	r

Synonyms

Synonyms	Comment	Organism
GDP-4-keto-6-deoxy-D-mannose reductase	-	Pseudomonas syringae
RMD	-	Pseudomonas syringae

General Information

General Information	Comment	Organism
malfunction	effect of deficiency in GDP-D-rhamnose biosynthetic genes, including GDP-4-keto-6-deoxy-D-mannose reductase, on lipopolysaccharide structure and pathogenicity in soybean, Glycine max cv. Shirofumi. The mutant strain DELTArmd shows highly reduced antimicrobial susceptibility with chloramphenicol, ampicillinm or spectinomycin. The mutant DELTArmd strain also shows increased degrees of adhesion to the polystyrene surface of the micro-titrate plates. It has higher hydrophobicity of the cell surface than the wild-type strain, but has normal flagellin glycans	Pseudomonas syringae

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)